Clinical outcomes of everolimus (EVE) for patients with advanced rectal neuroendocrine tumors (ARNETs) – A single-institutional retrospective study

#3624

Introduction: RADIANT-4 has established EVE as one of the standard-of-care for advanced NET G1–2 of gastrointestinal or lung origin, with a trend of a poorer efficacy of EVE in ARNET (median progression-free survival [PFS] of EVE: 17.3 months in advanced midgut NETs vs 7.4 months in the ARNETs). Little is known about the clinical outcomes of EVE for ARNET G1–2 and G3 in the real-world setting.

Aim(s): To evaluate the efficacy and safety of EVE for ARNET in the real-world setting.

Materials and methods: We extracted clinical data of patients with ARNET treated with EVE in the 1st line setting or after somatostatin analogue (SSA) and/or one line of chemotherapy from August 2016 to March 2022 at our institution. PFS, disease control rate (DCR), overall survival (OS), and safety were assessed.

Conference:

Presenting Author: Kim Y

Authors: Kim Y, Hirano H, Yamamoto S, Okita N, Shoji H,

Keywords: everolimus, rectal neuroendocrine tumor,